Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine.
Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology.
Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI).
Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy.
'Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,' said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. 'We're very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.'
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
Investors:Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@radiopharmtheranostics.com
Anne Marie Fields Precision AQ (Formerly Stern IR) E: annemarie.fields@precisionaq.com
Media:Matt WrightNWR CommunicationsP: +61 451 896 420E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/ Twitter – https://twitter.com/TeamRadiopharm Linked In – https://www.linkedin.com/company/radiopharm-theranostics/InvestorHub – https://investorhub.radiopharmtheranostics.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Council ditches bid to join iconic tourism strip
A Victorian council has ended a decade-long bid to be included in the renowned Great Ocean Road. The Glenelg Shire Council in far southwest Victoria is blaming state and national marketing campaigns for not including their region. Despite not being on the Great Ocean Road itself, the Glenelg council had been paying $80,000 a year to be part of the Great Ocean Road Regional Tourism Board. In a statement on the council website, posted earlier this month, the council says it is time to cut the chord. 'From 2015, Glenelg Shire Council have been a member of the Great Ocean Road Regional Tourism Board (GORRT),' a spokesperson said. 'Council has found that although GORRT have been strong in their advocacy and attempts to link the Glenelg Shire to the Great Ocean Road, the Glenelg Shire is simply not officially recognised by our state and federal partners as being part of the Great Ocean Road. 'We are regularly omitted from marketing, tourism campaigns and strategies.' The Great Ocean Road generates $1.9bn of economic activity each year, the state government says, creating 9800 local jobs. Tourism Australia launched its new major campaign last week, and the only Victorian location featured was the Twelve Apostles, which is on the western half of the tourism strip. The Glenelg Shire is west of the actual Great Ocean Road, despite paying $80,000 a year to the road's tourism board. Membership gives businesses and organisations access to marketing on tourism websites. 'Council has chosen not to continue with GORRT, instead redirecting the $80,000 per year membership fee to directly invest in tailored opportunities that better align with the unique needs and potential of our region,' the council spokesperson said. The Glenelg Shire will instead focus on promoting its nationally recognised Kelpie Festival, and the UNESCO World Heritage-listed Budj Bim Cultural Landscape; the first place in Australia to be recognised solely for its Aboriginal cultural values. A state government spokesperson said Great Ocean Road Regional Tourism Board was in charge of tourism for the region. 'We will continue to work with Glenelg Shire to encourage visitors to visit southwest Victoria and experience the best of the Great Ocean Road,' the spokesperson said.
Yahoo
an hour ago
- Yahoo
Giant Stick Insect Found Hiding in Rainforest May Be Australia's Heaviest
A colossal stick insect found living in the highland rainforest of northeastern Australia could be the chonkiest (read: heaviest) bug the continent has to offer. Acrophylla alta, as the species has been named, weighs up to 44 grams (1.6 ounces) – comparable to a golf ball. In length, it measures around 41 cm (16 inches) with its legs outstretched, significantly longer than the average human forearm. "There are longer stick insects out there [in the region], but they're fairly light bodied," says natural scientist Angus Emmott, formerly of Australia's James Cook University, now retired. "From what we know to date, this is Australia's heaviest insect." The newly discovered bug makes its home high in the canopy of the Atherton Tablelands, a highland rainforest in tropical Queensland in Australia. Here, the trees are old, and can be up to 30 meters (100 feet) high. Many insect species have been understudied and overlooked, simply because their habitat is so hard for humans to access. Related: 'Bone Collector' Caterpillar Wears Dead Bugs to Steal Prey From Spiders In the case of A. alta, there's another confounding factor: in its natural habitat, the insect is extremely well camouflaged, in spite of its humungous size and weight. Because Atherton is a tropical region, however, weather events such as storms can sometimes rattle insects loose from the canopy. A. alta was discovered because amateur naturalists came across it at lower altitudes than these kinds of insects are typically seen, and uploaded their observations to iNaturalist. There, they were spotted by entomologist Ross Coupland, who recruited Emmott to investigate the mysterious species. They managed to observe and collect some specimens – and, crucially for identification, the species' eggs. "Every species of stick insect has their own distinct egg style," Emmott explains. "They've all got different surfaces and different textures and pitting, and they can be different shapes. Even the caps on them are all very unique." The insect's hefty weight, the researchers say, could be an adaptation that helps it thrive in the treetops of Atherton, where conditions are cool and wet. A higher body mass reduces the rate at which thermal energy is lost, which could be beneficial for the stick insect's egg development. Further research would be needed to confirm this theory, though. The research also underscores just how little we know about the world around us, when an insect as chonky as A. alta can evade detection for all this time. "The discovery of such a large, new species of insect is testament to the importance of protecting remaining, biologically diverse habitats and ecosystems, as there may be further species of phasmid and other insects awaiting discovery and description therein," the researchers write. Their discovery has been published in Zootaxa. Related News Evidence of World-Changing Comet Explosion 12,800 Years Ago Found in The Ocean 'Hot Blob' Heading For New York Following Ancient Greenland Rift Prehistoric Air Has Been Reconstructed From Dinosaur Teeth in an Amazing First Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
Deutsche Bank Raises Albemarle (ALB) Target, Signals Cautious Optimism on Lithium
Albemarle Corporation (NYSE:ALB) is one of the best battery tech stocks to buy right now. On August 4, Deutsche Bank raised its price target for Albemarle from $65 to $74 while keeping a Hold rating. The new target shows they feel a little more positive about the company, but they are still being cautious. A team of scientists in a laboratory observing the sophisticated engineering of specialty chemicals. Albemarle has halted its U.S. lithium refinery project, cut capital spending by 50%, closed its Chengdu plant, shifted Chinese production to carbonate, and began commercial output from its Kemerton facility to counter weak prices and preserve margins. Albemarle Corporation (NYSE:ALB) is a leading producer of lithium, which is used in batteries for electric cars. Because the world is slowly but surely switching to electric vehicles, the need for lithium is growing. That makes the company worth considering for the long term. Even with the price target going up, the expected gain is only about 7%. This is not a big return in the short run. But Albemarle is in a good spot for the future, since more clean energy and battery use are likely coming. Albemarle Corporation (NYSE:ALB) extracts lithium, a vital input for electrochemical storage units powering electric mobility, grid stabilization systems, and portable electronic apparatuses across expanding clean energy and digital ecosystems. While we acknowledge the potential of ALB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 10 Best Military Tech Stocks to Buy Now Disclosure: None.
